CJC-1295 and Metabolism: How This GH Secretagogue Affects Energy Expenditure

What CJC-1295 Actually Is (and Is Not)

CJC-1295 is a synthetic 29-amino-acid peptide that mimics endogenous GHRH, the hypothalamic signal that triggers GH release from the anterior pituitary. The "DAC" variant (Drug Affinity Complex) adds a lysine-maleimide linker that covalently binds circulating albumin, extending the plasma half-life from roughly 30 minutes (native GHRH) to 6 to 8 days [1].

Two Forms in Clinical Use

Prescribers and patients encounter two distinct compounds under the CJC-1295 label. CJC-1295 without DAC (also called modified GRF 1-29, or Mod-GRF 1-29) has a half-life of 30 minutes and must be dosed 2 to 3 times daily or immediately before sleep to align with the natural nocturnal GH pulse. CJC-1295 with DAC maintains a flat, elevated GH baseline for up to a week per injection, which produces a different endocrine pattern than pulsatile release. The metabolic implications differ between these two profiles, and confusing them leads to both under-dosing and misinterpretation of lab results.

Regulatory and Compounding Context

Neither form has an FDA-approved indication. Both are dispensed as compounded preparations under 503A pharmacy rules, meaning they require a patient-specific prescription from a licensed practitioner [2]. The FDA's 2024 guidance on peptide compounding created uncertainty for several secretagogues; practitioners should verify current formulary status with their compounding pharmacy before initiating therapy.

How CJC-1295 Drives GH and IGF-1 Elevation

The foundational human pharmacokinetic data come from Teichman et al. (2006), a double-blind, placebo-controlled trial published in the Journal of Clinical Endocrinology and Metabolism. The trial enrolled 65 healthy adults aged 21 to 61 years and tested single subcutaneous doses of CJC-1295 (with DAC) ranging from 30 to 120 mcg/kg [1].

The Teichman 2006 Findings in Detail

Mean GH concentrations rose 2- to 10-fold above baseline within 2 hours of injection and remained significantly elevated for up to 6 days at the 60 mcg/kg dose. IGF-1 increased 1.5- to 3-fold and stayed elevated for up to 8 days. Critically, the GH increases occurred without obliterating the underlying pulsatile architecture: subjects still showed GH peaks at night, superimposed on the elevated trough [1]. That preservation of pulsatility matters metabolically, because pulsatile GH is more lipolytically potent per unit than a continuous infusion of equivalent total GH, as shown in a crossover study by Jaffe et al. (1998) [3].

IGF-1 as the Downstream Metabolic Mediator

IGF-1, produced primarily in the liver in response to GH, mediates several of CJC-1295's downstream effects, including increased protein synthesis and improved insulin sensitivity in skeletal muscle. However, IGF-1 also has counter-regulatory effects on GH secretion through a negative-feedback loop. At sustained pharmacologic IGF-1 levels, the feedback may dampen further GH pulses. This is one clinical reason practitioners often limit CJC-1295 dosing to 5 days on, 2 days off, rather than daily administration.

CJC-1295, Lipolysis, and Fat Oxidation

Growth hormone is a counter-regulatory hormone. It opposes insulin's lipogenic effects in adipose tissue by activating hormone-sensitive lipase (HSL) and suppressing lipoprotein lipase (LPL), the enzyme that loads circulating fatty acids into fat cells [4]. The net result is increased free fatty acid (FFA) release from adipose stores and a shift in whole-body substrate oxidation toward fat.

The Substrate-Shift Mechanism

In GH-deficient adults given GH replacement, indirect calorimetry studies show that fat oxidation rises by roughly 15 to 25% within the first 4 weeks, while carbohydrate oxidation falls proportionally [5]. Resting metabolic rate typically increases by 5 to 10% over a 3 to 6 month course, an effect attributable partly to the expansion of metabolically active lean mass and partly to the direct thermogenic signaling of GH and IGF-1 on brown adipose tissue.

CJC-1295 has not been studied by indirect calorimetry in a published randomized trial as of mid-2025. Practitioners extrapolate from GH-replacement data, which is methodologically defensible given that the proximate effector (GH) is the same, but the magnitude of effect may differ because CJC-1295 produces lower peak GH levels than exogenous recombinant human GH (rhGH).

Fat-Mass Changes in the GH-Replacement Literature

The longest-duration controlled data come from the Norditropin literature. A Cochrane meta-analysis of GH replacement in GH-deficient adults (17 RCTs, N=522) reported a mean fat-mass reduction of 2.5 kg and lean-mass gain of 2.8 kg after 6 months of treatment [6]. These changes occurred at GH doses producing peak IGF-1 levels similar to those Teichman et al. Observed with CJC-1295 at 60 mcg/kg. The analogy is imperfect but represents the strongest available proxy data.

Visceral vs. Subcutaneous Adipose

GH preferentially mobilizes visceral fat. In a 12-month RCT by Johannsson et al. (1997), adults with GH deficiency showed a 30% reduction in visceral adipose area on CT scan, compared with a 13% reduction in subcutaneous fat, after GH replacement [7]. Visceral fat loss is clinically meaningful because visceral adiposity drives insulin resistance, hepatic steatosis, and cardiovascular risk independent of total body weight. If CJC-1295 reproduces even 60% of this effect, the cardiometabolic benefit may exceed what the scale shows.

Energy Expenditure: Resting, Active, and Total

Resting Metabolic Rate

GH and IGF-1 increase protein synthesis in skeletal muscle, and muscle tissue burns roughly 13 kcal/kg/day at rest, compared with 4.5 kcal/kg/day for fat tissue. Adding 2 kg of lean mass over 6 months, a plausible CJC-1295 outcome extrapolated from GH-replacement data, raises resting metabolic rate by approximately 26 kcal/day. That sounds modest, but over a year it represents roughly 9,500 kcal, or the equivalent of about 2.7 lbs of fat, without any change in activity level.

Thyroid Hormone Interaction

GH directly stimulates the conversion of thyroxine (T4) to the more metabolically active triiodothyronine (T3) by upregulating type 1 deiodinase in hepatic tissue [8]. Patients with subclinical hypothyroidism who begin GH secretagogue therapy may see an apparent worsening of thyroid labs as this T4-to-T3 shift occurs. Monitoring a full thyroid panel (TSH, free T4, free T3) at baseline and at 8 weeks is reasonable clinical practice.

Exercise Combination Without the Marketing Language

CJC-1295's metabolic effects are not independent of physical activity. GH receptor density in skeletal muscle increases with resistance training, meaning trained individuals mount a larger IGF-1 response to any given GH stimulus. A patient who combines CJC-1295 with structured resistance exercise 3 to 4 days per week will likely see faster lean-mass accrual than one who remains sedentary. This is not a branding claim; it reflects the well-characterized biology of GH receptor upregulation after mechanical loading [9].

Glucose Metabolism: The Insulin Resistance Trade-Off

GH is diabetogenic at high or sustained levels. It reduces insulin sensitivity at the post-receptor level in skeletal muscle, increasing fasting glucose and blunting glucose disposal during a meal. Teichman et al. Did not observe clinically significant glucose changes at their tested doses [1], and the GH levels CJC-1295 achieves are substantially lower than those seen in acromegaly. Still, metabolic monitoring is warranted.

Who Needs Closer Monitoring

Patients with pre-existing insulin resistance, type 2 diabetes (T2D), or fasting glucose above 100 mg/dL deserve baseline and 8-week fasting glucose and HbA1c checks. The American Diabetes Association's 2024 Standards of Care note that GH excess consistently impairs glucose tolerance and that even modest GH elevation may require diabetes medication adjustment in susceptible patients [10].

Practical Dosing to Minimize Glucose Impact

Dosing CJC-1295 (without DAC) at night, in the hour before sleep, aligns GH release with the physiologic nocturnal GH surge that healthy adults already experience. During sleep, insulin sensitivity is naturally reduced and free fatty acids are the primary fuel. This timing concentrates the lipolytic benefit during a period when modest insulin antagonism is least harmful. Typical compounded doses run 100 to 300 mcg subcutaneously at night.

Body Composition: What the Evidence Actually Supports

The table below summarizes a HealthRX clinical framework for mapping expected CJC-1295 metabolic outcomes to patient phenotype, based on published GH-axis physiology and the Teichman pharmacokinetic profile. This framework will be updated as the HealthRX outcomes registry accumulates data.

CJC-1295 Expected Metabolic Response by Phenotype

| Patient Phenotype | Primary Expected Benefit | Time to Measurable Change | Key Monitoring Point | |---|---|---|---| | GH-deficient adult (confirmed by stimulation test) | Fat-mass reduction, lean-mass gain | 8 to 12 weeks | IGF-1 at 6 weeks | | Metabolically healthy, body-fat >28% (M) / >38% (F) | Modest lipolysis, visceral fat reduction | 12 to 16 weeks | Fasting glucose, waist circumference | | Pre-diabetic (fasting glucose 100 to 125 mg/dL) | Possible lean-mass gain; fat loss uncertain | Monitor closely at 8 weeks | HbA1c, fasting insulin | | Active resistance trainer, normal BMI | Lean-mass accrual, recovery improvement | 6 to 10 weeks | IGF-1, lean mass via DEXA | | Age >60, low IGF-1 (<100 ng/mL) | IGF-1 restoration toward mid-normal range | 8 weeks | IGF-1, glucose, fluid balance |

What DEXA Shows vs. What the Scale Shows

Patients who start CJC-1295 frequently report no change in body weight during the first 4 weeks, despite subjective improvements in body composition. This reflects two simultaneous processes: lean-mass accumulation and fluid redistribution driven by GH's sodium-retaining effects in the renal tubule. DEXA scanning at baseline and 3 months gives a cleaner picture than the bathroom scale. If DEXA is not accessible, waist circumference plus a validated body-fat percentage tool (e.g., 4-site skinfold or bioelectrical impedance) at standardized hydration status is an acceptable substitute.

Lean Mass Accrual: Realistic Expectations

Extrapolating from the Norditropin Cochrane data and adjusting downward 40% to account for the lower GH peaks produced by CJC-1295 vs. RhGH, a reasonable expectation is 1.2 to 1.7 kg of lean mass gained over 6 months in a training individual. That number is not dramatic, but lean mass accrual is cumulative and compounds over years of consistent therapy in a way that episodic dieting does not.

Drug Interactions and Clinical Considerations

Glucocorticoids

Glucocorticoids (prednisone, hydrocortisone, dexamethasone) suppress endogenous GHRH release and blunt pituitary GH responsiveness. A patient on chronic glucocorticoid therapy may derive significantly less metabolic benefit from CJC-1295. The 2019 Endocrine Society guidelines on adult GH deficiency explicitly caution that GH replacement efficacy is reduced in glucocorticoid-treated patients [11].

Thyroid Hormone Replacement

Untreated or undertreated hypothyroidism limits GH axis response. The pituitary requires adequate thyroid hormone to produce a full GH pulse. Patients with TSH above 3.0 mIU/L should have thyroid status optimized before beginning CJC-1295 therapy to avoid a muted response.

Combination With Ipamorelin

Most 503A compounders dispense CJC-1295 co-formulated with ipamorelin, a selective GH secretagogue receptor (GHSR) agonist. CJC-1295 acts on GHRH receptors while ipamorelin acts on ghrelin receptors (GHSR-1a), creating complementary and additive GH release through separate receptor populations. The combined GH pulse is approximately 2- to 3-fold larger than either agent alone in animal models, though head-to-head human pharmacokinetic data for the combination are not published in peer-reviewed literature as of mid-2025.

Monitoring Protocol for Metabolic Optimization

A rational monitoring schedule follows the GH axis kinetics established in the Teichman trial and standard GH-replacement practice:

• Baseline: IGF-1, fasting glucose, HbA1c, fasting insulin, full thyroid panel (TSH, free T4, free T3), comprehensive metabolic panel, DEXA or body-fat percentage.
• Week 6 to 8: IGF-1 (dose-adjust to keep IGF-1 in the upper third of age-adjusted reference range, not above the upper limit of normal), fasting glucose.
• Month 3: Repeat DEXA or body-fat assessment, full metabolic panel, IGF-1.
• Month 6: Full panel repeat; reassess clinical goals and continuation.

Target IGF-1 is typically 200 to 300 ng/mL in adults aged 30 to 60 years, which corresponds to the upper-normal range for a 25-year-old. Operating above the upper limit of normal increases the theoretical risk of IGF-1-driven cell proliferation, a consideration that informs the Endocrine Society's guidance against empiric GH use in patients without confirmed deficiency [11].

Safety Profile and Adverse Effects Relevant to Metabolism

Injection-site reactions (erythema, transient nodule) are the most common adverse effect reported in the Teichman trial, affecting 16 of 65 participants at the 120 mcg/kg dose [1]. Fluid retention, reflecting GH's sodium-retaining effect on the renal tubule, occurs in 10 to 20% of new users and typically resolves within 2 to 4 weeks as the kidney adapts. Carpal tunnel syndrome, a recognized side effect of both GH replacement and acromegaly, has been anecdotally reported with CJC-1295 at higher doses but is not documented in controlled trial data.

A specific safety note for metabolic patients: GH stimulates lipolysis acutely and briskly, raising serum FFA levels within 2 to 4 hours of a dose. In patients with poorly controlled T2D, acutely elevated FFAs can worsen hepatic insulin resistance and raise fasting glucose the following morning. Any patient starting CJC-1295 with HbA1c above 7.0% should have glucose monitored weekly for the first month.